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The ability of bacteria to form biofilms hinders any conventional treatment for chronic infections 
and has serious socio-economic implications. For this purpose, a nanocarrier capable of 
overcoming the barrier of the mucopolysaccharide matrix of the biofilm and releasing its loaded-
antibiotic within this matrix would be desirable. Herein, we developed a new nanosystem based on 
levofloxacin (LEVO)-loaded mesoporous silica nanoparticles (MSNs) decorated with the lectin 
concanavalin A (ConA). The presence of ConA promotes the internalization of this nanosystem 
into the biofilm matrix, which increases the antimicrobial efficacy of the antibiotic hosted within 
the mesopores. This nanodevice is envisioned as a promising alternative to conventional 
treatments for infection by improving the antimicrobial efficacy and reducing side effects. 
Statement of Significance
The present study is focused on finding an adequate therapeutic solution for the treatment of bone 
infection using nanocarriers that are capable of overcoming the biofilm barrier by increasing the 
therapeutic efficacy of the loaded antibiotic. For this purpose, we present a nanoantibiotic that 
increases the effectiveness of levofloxacin to destroy the biofilm formed by the model bacterium 
E. coli.. This work opens new lines of research in the treatment of chronic infections based on 
nanomedicines.
Keywords 
Biofilm; Bacterial infection; Lectin; Mesoporous Silica Nanoparticles; Nanomedicine; Synergistic 
Combination; Targeting.
1. Introduction
Presently, antimicrobial resistance (AMR) is a major threat to global health with serious 
socioeconomic implications [1,2]. Therefore, a post-antibiotic era is emerging to replace 
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ineffective conventional antimicrobial treatments [3-5]. For this purpose, the combination of AMR 
and bacterial biofilm formation leads to infections that are almost unmanageable [6]. A biofilm is a 
bacterial community in which bacteria are embedded into an extracellular matrix mainly composed 
of polysaccharides. It renders the microorganisms a natural mechanism of defense against external 
aggressions including antibiotics and the immune system [7]. 
MSNs have recently been used in nanomedicine owing to their efficiency in the host and their 
ability to protect and transport diverse drugs and locally release them on reaching the target tissue 
[8-10]. Further, MSNs have proven to be a multifunctional and versatile solution in the treatment 
of bacterial infections, as they have advantages at all stages of treatment, including early detection, 
drug release, targeting the bacteria or the biofilm, antifouling surfaces, and adjuvant capacity [11]. 
Specifically, once the biofilm has been formed, the use of these nanocarriers could be quite potent, 
as their surface can be functionalized with targeting agents, thereby increasing their affinity toward 
biofilms and favoring higher treatment efficacy [9-15]. 
Lectins such as ConA are glycoproteins present in a variety of organisms, and most of them are 
isolated from plant components [16]. Moreover, they have the ability to weakly bind to glycans 
with high specificity, hence forming glycoconjugates [17]. In reality, ConA has been successfully 
used to design antitumor drug-loaded nanoparticles that can selectively bind and internalize into 
cancer cells overexpressing membrane glycans [18,19]. Biocompatibility was also demonstrated, 
as no significant cell death was observed after incubation with MC3T3-E1 (mouse preosteoblastic) 
cells at concentrations up to 144 µg/mL [19]. As glycan-type polysaccharides are also present in 
the bacterial biofilm, we hypothesized that ConA could be used to target MSNs toward 
extracellular biofilm matrix. In fact, although the use of ConA for the treatment of infections due 
to planktonic bacteria is more widespread [20-22], its application once the biofilm is formed is 
very limited, and there appears to be a few publications on this subject. When uniquely present, 
ConA can be used for detection [23,24], as shown in a single publication in which ConA is part of 
a nanosystem used for treatment purposes [25]. In addition, this appears to be the initial 
demonstration of ConA anchorage to the surface of nanoparticles, which presents a significant 
antibiotic action, without the need for a loaded drug. However, it is true that the combined action 
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of ConA and a therapeutic would be thought to intensify the antimicrobial character of the system. 
Herein, we report the design of a new nanoantibiotic consisting of MSNs loaded with an 
antimicrobial agent (LEVO) and grafted with ConA onto their outermost surface, which has been 
proved to selectively recognize and bind to certain glycans (Fig. 1).
2. Materials and Methods
2.1 Reagents
Tetraethylorthosilicate (TEOS, 98%), n-cetyltrimethylammonium bromide (CTAB, ≥99%), 
sodium hydroxide (NaOH, ≥98%), ammonium nitrate (NH4NO3, ≥98%), sodium carbonate 
(Na2CO3, ≥99.5%), hydrochloric acid (HCl, 37%), Rhodamine B isothiocyanate (RITC, ≥98%), 
(3-aminopropyl) triethoxysilane (APTES, ≥98%), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC, ≥98%), N-hydroxysulfosuccinimide sodium salt (sulfo-
NHS, ≥98%), phosphate-buffered saline (PBS, 10x), phosphotungstic acid hydrate (PTA, reagent 
grade), and concanavalin A from Canavalia ensiformis (jack bean) (ConA, Type VI lyophilized 
powder) were purchased from Sigma-Aldrich (St. Louis, USA). 3-(Triethoxysilyl)propylsuccinic 
anhydride (SATES, 95%) was purchased from ABCR (Karlsruhe, Germany). All other chemicals 
such as absolute ethanol were purchased from Panreac Química SLU (Castellar del Valles, 
Barcelona, Spain). All reagents were used as received without further purification. Ultrapure 
deionized water with a resistivity of 18.2 MΩ was obtained using a Millipore Milli-Q plus system 
(Millipore S.A.S., Molsheim, France). Levofloxacin (LEVO, C18H20FN3O4, 98 %w) was purchased 
from Sigma-Aldrich. 
2.2 Characterization techniques
Powder X-ray diffraction (XRD) experiments were performed on a Philips X’Pert diffractometer 
equipped with Cu Kα radiation (wavelength 1.5406 Å) (Philips Electronics NV, Eindhoven, The 
Netherlands). XRD patterns were collected in the 2ɵ range between 0.6° and 8° with a step size of 
0.02° and counting time of 5 s per step. Thermogravimetric (TG) measurements were performed 
using a PerkinElmer Pyris Diamond TG/DTA (California, USA), with 5 ºC min-1 heating ramps, 
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from room temperature (RT) to 600 ºC. Fourier transform infrared spectroscopy (FTIR) was 
carried out using a Nicolet (Thermo Fisher Scientific, Waltham, MA, USA) Nexus spectrometer 
equipped with GoldenGate attenuated total reflectance (ATR) accessory (Thermo Electron 
Scientific Instruments LLC, Madison, WI, USA). Morphology, mesostructural order, and 
nanoparticle functionalization were studied by high-resolution transmission electron microscopy 
(HRTEM) with a JEOL JEM 1400 instrument, equipped with a CCD camera (JEOL Ltd., Tokyo, 
Japan). Sample preparation was performed by dispersing the sample in distilled water and 
subsequent deposition onto carbon-coated copper grids. A 1% PTA solution (pH 7.0) was used as 
the staining agent to visualize the organic coating around MSNs. 
To determine the evolution of the size and surface charge of nanoparticles by dynamic light 
scattering (DLS) and zeta (ζ) potential measurements, respectively, a Zetasizer Nano ZS (Malvern 
Instruments, United Kingdom) equipped with a 633-nm “red” laser was used. DLS measurements 
were directly recorded in ethanolic colloidal suspensions. Measurements of ζ potential were 
recorded in aqueous colloidal suspensions. For this purpose, 1 mg of nanoparticles was added to 
10 mL of solvent, followed by sonication for 5 min to obtain a homogeneous suspension. In both 
cases, measurements were recorded by placing 1 mL of the suspension (0.1 mg mL-1) in DTS1070 
disposable folded capillary cells (Malvern Instruments). The textural properties of the materials 
were determined by N2 adsorption porosimetry by using a Micromeritics ASAP 2020 
(Micromeritics Co., Norcross, USA). To perform N2 measurements, 20-30 mg of each sample was 
previously degassed under vacuum for 24 h at 40 ºC. Surface area (SBET) was determined using the 
Brunauer-Emmett-Teller (BET) method, and pore volume (VP) was estimated from the amount of 
N2 adsorbed at a relative pressure of approximately 0.97. The pore size distribution between 0.5 
and 40 nm was calculated from the adsorption branch of the isotherm by the Barrett-Joyner-
Halenda (BJH) method. Mesopore size (DP) was determined from the maximum of the pore size 
distribution curve. 
2.3 Synthesis of pure-silica MSNs (MSN)
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Bare MSNs, denoted as MSNs, were synthesized by the modified Stöber method using TEOS as 
the silica source in the presence of CTAB as the structure-directing agent. Briefly, 1 g of CTAB, 
480 mL of H2O, and 3.5 mL of NaOH (2 M) were added to a 1,000 mL round-bottom flask. The 
mixture was heated to 80 ºC and magnetically stirred at 600 rpm. When the reaction mixture was 
stabilized at 80 ºC, 5 mL of TEOS was added dropwise at a rate of 0.33 mL min-1. The white 
suspension obtained was further stirred for 2 h at 80 ºC. The nanoparticles were collected by 
centrifugation, washed twice with water and twice with ethanol, and stored in ethanol suspension.
For cellular internalization studies, rhodamine-labeled MSNs were synthesized. For this purpose, 1 
mg of FITC and 2.2 µL of APTES were dissolved in 100 µL of ethanol and allowed to react for 2 
h. Then the reaction mixture was added to 5 mL of TEOS as previously described.
2.4. Functionalization of MSN with carboxylic acid groups (MSNSATES)
With the aim of preferentially grafting carboxylic acid groups to the external surface of MSNs, 
500 mg of CTAB-containing MSNs was taken in a three-neck round-bottom flask and dried at 80 
ºC under vacuum for 24 h. Then 125 mL of dry toluene was added, and the flask was placed in an 
ultrasonic bath and subjected to several sonication cycles for 5 min until an adequate suspension of 
nanoparticles was achieved. Then 300 µL of SATES was added, keeping the reaction under 
nitrogen atmosphere at 90 ºC for 24 h. The reaction mixture was centrifuged and washed three 
times with water and ethanol. The surfactant was removed by ionic exchange by soaking 1 g of 
nanoparticles in 500 mL of NH4NO3 solution (10 mg mL-1) in ethanol (95%) at 65 ºC overnight 
under magnetic stirring. The nanoparticles were collected by centrifugation, washed three times 
with ethanol, and stored in ethanol suspension.  
2.5. ConA grafting to MSNSATES (MSNConA)
Sixteen milligrams of MSNSATES was taken in a vial and suspended in 2 mL of PBS, pH 7.4, and 
subjected to several sonication cycles for 5 min until an adequate suspension was achieved. After 
that, 32 mg of EDC was added and the mixture was stirred at R.T. for 40 min. Then 14 mg of 
sulfo-NHS was added, and the reaction was stirred for 5 h; this was followed by addition of 32 mg 
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of ConA, and the mixture was allowed to react overnight at R.T. Finally, the samples were 
centrifuged, washed twice with sterile 1x PBS, and suspended in fresh PBS.
2.6. Loading with levofloxacin (MSN@LEVO and MSNConA@LEVO)
MSN and MSNSATES samples (12 mg) were obtained by centrifugation; these samples were 
suspended in 2 mL of LEVO solution (2.85 mg/mL) under stirring for 24 h. After that, 
MSN@LEVO and MSNSATES@LEVO samples were centrifuged, washed once with EtOH and 
sterile 1x PBS, and suspended in 2 mL of fresh PBS.
Then 24 mg of EDC was added to (MSNSATES@LEVO), and the mixture was stirred at R.T. for 40 
min. Then 14 mg of NHS was added, and the reaction was further stirred for 5 h; this was followed 
by addition of 24 mg of ConA, and the reaction mixture was allowed to react overnight at R.T. 
Finally, the samples were centrifuged, washed twice with sterile 1x PBS, and suspended in 1 mL 
of fresh PBS, affording MSN@LEVO and MSNConA@LEVO. Both suspensions were divided as 
two batches: one was dried to perform release experiments and the other one was used for viability 
experiments. Quantitative determination of the loaded LEVO was performed by elemental CHN 
chemical analyses in a PerkinElmer 2400 CHN and a LECO CHNS-932 thermo analyzer and TG 
analysis (TGA) in a PerkinElmer Pyris Diamond thermobalance. CHN analyses include low 
analytical ranges of 0.001–3.6 mg for carbon, 0.001–1.0 mg for hydrogen, 0.001–6.0 mg for 
nitrogen, and 0.001–2.0 mg for oxygen.
2.7. “In vial” cargo release assays
Dried MSN@LEVO and MSNConA@LEVO (4 mg) were suspended in 0.45 mL of 1x PBS and 
subjected to sonication until a good suspension was achieved. Then 170 μL of each nanoparticle 
suspension was filled into a reservoir cap sealed with a dialysis membrane (molecular weight 
cutoff: 12,000 g mol-1), allowing the released LEVO molecules to pass into the cuvette (which was 
completely filled with 1x PBS), while the relatively large particles were held back. The experiment 
was performed in triplicate. The amount of LEVO released was determined by fluorescence 
measurements (λexc = 292 nm, λem = 494 nm) of the solution recorded on a BioTek 
Spectrofluorimeter (BioTek Instruments GmbH, Germany). Different calibration lines have been 
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calculated for a concentration range of 12–0.01 g/mL. To determine the effectiveness of the 
LEVO dosages released from the different MSNs against bacterial growth, 100 L of each dosage 
was inoculated in 900 L of PBS containing 108 bacteria per mL and incubated overnight. The 
presence or absence of bacteria, as well as their quantification, was determined by counting the 
colony-forming units (CFUs) in agar. For this purpose, 10 L of this solution was seeded onto 
tryptic soy agar (TSA) and incubated at 37 ºC overnight, followed by subsequent counting. 
Controls containing bacteria were also set, and the experiments were performed in triplicate.
2.8. Internalization assays in E. coli biofilm
In vitro targeting assays of LEVO-free nanosystems toward the bacterial biofilm were performed. 
For this purpose, E. coli biofilms were previously developed onto poly-D-lysine-coated round 
cover glasses by suspending the round cover glasses in a bacterial suspension of 108 bacteria per 
mL for 48 h at 37 ºC under orbital stirring at 100 rpm. In this case, the medium used was 66% 
THB + 0.2% glucose to promote a robust biofilm formation. After that, the round cover glasses 
containing the biofilm were placed onto 24-well culture plates (CULTEK) containing 1.5 mL of 
new medium in each well. Then, 0.5 mL of a suspension of red-labeled MSN materials in PBS at 
final concentrations of 5, 10, and 50 g/mL was added. After 90 min of incubation, the glass discs 
were washed three times with sterile PBS, and 3 L/mL of Syto was added to stain the live 
bacteria, and 5 L of calcofluor solution was added to stain the mucopolysaccharides of the 
biofilm (extracellular matrix) in blue to specifically determine the biofilm formation. Both 
reactants were incubated for 15 min at RT. Controls containing the bacterial biofilm were also set. 
Biofilm formation was examined using an Olympus FV1200 confocal microscope, and eight 
photographs (60X magnification) were taken for each sample.
2.9. Antimicrobial effects against gram-negative E. coli biofilm
Effectiveness of the LEVO-loaded nanosystems against the biofilm was also determined. For this 
purpose, two different assays were performed using mature E. coli biofilm. First, confocal assays 
were conducted, wherein E. coli biofilms were previously developed onto poly-D-lysine-coated 
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round cover glasses as done previously. Then, 0.5 mL of a suspension of different nanoparticles in 
THB at different concentrations (5, 10, and 50 g/mL) was added. After 90 min of incubation, the 
glass discs were washed three times with sterile PBS, and 3 L/mL of Live/Dead Bacterial 
Viability Kit (BacLightTM) was added. In addition, 5 L/mL of calcofluor solution was added to 
stain the extracellular matrix in blue to specifically determine the biofilm formation. Both 
reactants were incubated for 15 min at RT. Controls containing the bacterial biofilm were also set. 
Biofilm formation was examined using an Olympus FV1200 confocal microscope, and eight 
photographs (40X magnification) were taken for each sample. To perform quantitative analyses, 
the surface area covered with live bacteria (green) and extracellular matrix (blue) was calculated 
from eight images using ImageJ software (National Institutes of Health, Bethesda, MD). All 
images are representative of three independent experiments. Second, quantitative antibiofilm 
assays were carried out by calculating the reduction of CFU/mL. Previously, E. coli biofilms were 
seeded onto 24-well plates (CULTEK) by incubating 106 bacteria/mL for 48 h at 37 ºC under 
orbital stirring at 100 rpm. In this case, the medium used was 66% THB + 0.2% glucose to 
promote a robust biofilm formation. After that, the biofilms were gently washed, and 1 mL of a 
suspension of MSN materials in THB at concentrations of 5, 10, and 20 g/mL was added. After 
24 h of incubation, the plates were washed three times with sterile PBS and sonication was applied 
for 1-10 min in a low-power bath sonicator (Selecta, Spain) to disperse the biofilm in a total 
volume of 1 mL of PBS. The sonicated sample was then serially diluted 7 times to 1:10 in a final 
volume of 1 ml. The experiments were performed in triplicate for each dilution of three different 
experiments. Quantification of the bacteria was carried out in a 1 mL volume using the drop plate 
method [26]. Five 10 µL drops of each dilution were inoculated on tryptic soy agar (TSA) (Sigma-
Aldrich, USA) plates, which were incubated for 24 h at 37ºC. The mean count of the 5 drops of 
each dilution was calculated, and then, the average counting for all dilutions was calculated. 
2.10 Cell viability in presence of preosteoblastic cells 
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Cell culture studies were performed with the mouse osteoblastic cell line MC3T3-E1 
(Subclone 4, CRL-2593; American Type Culture Collection, Manassas, VA, USA). First, 
cells were plated (24-well plates (CULTEK)) at a density of 20,000 cells·cm−2 in 1 mL of 
α-minimum essential medium containing 10% heat-inactivated fetal bovine serum and 1% 
penicillin (BioWhittaker Europe)−streptomycin (BioWhittaker Europe) at 37 °C in a 
humidified atmosphere of 5% CO2 and incubated for 24 h. After that, different 
concentrations of MSNs, that is, 5, 10, and 50 g/mL, were added to each culture. Cell 
viability after 24 h of incubation with different MSNs was analyzed. Cell growth was 
determined by the CellTiter 96 AQueous assay (Promega, Madison, WI, USA), a 
colorimetric method for determining the number of living cells in culture. The CellTiter 
96 AQueous one-solution reagent [40 μL, containing 3-(4,5-dimethythizol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) and an electron-
coupling reagent (phenazine ethosulfate) that allows its combination with MTS to form a 
stable solution] was added to each well, and the plates were incubated for 4 h. The 
absorbance at 490 nm was then measured on a Unicam UV-500 UV–visible 
spectrophotometer.
2.11 Statistical Analysis
All data are expressed as the mean ± standard deviation of a representative of three independent 
experiments carried out in triplicate. Statistical analysis was performed using Statistical Package 
for the Social Sciences (SPSS) version 19 software. Statistical comparisons were made by analysis 
of variance (ANOVA). The Scheffé test was used for post hoc evaluations of differences among 
groups. In all of the statistical analyses, p <0.05 was considered as statistically significant.
3. Results and Discussion
3.1 Preparation and characterization of the nanosystems
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The nanoantibiotic, denoted as MSNConA@LEVO, was synthesized through several steps (Fig. 2). 
Briefly, pure silica MSNs were synthetized by the well-known modified Stöber method [27] and 
externally functionalized by grafting an alkoxysilane-bearing carboxylic acid groups, which allows 
the final anchorage of ConA by reaction with the amine groups present in the protein. LEVO 
loading was carried out by the impregnation method in ethanol [13] and always before ConA 
grafting to prevent protein denaturation. 
With the aim of confirming the chemical grafting of the different functional groups, MSN, 
MSNSATES, and MSNConA were characterized by different techniques, and the results were 
compared after each reaction step. Using FTIR spectroscopy, we could follow the nanoparticle 
functionalization process. The change from a clean spectrum in the 1500-2000 cm-1 range of MSN 
to the presence of a signal at 1637 cm-1, characteristic of the stretching vibration of acid groups, 
was observed in MSNSATES (Fig. 3). Finally, in the FTIR spectrum of MSNConA, the amide bonds 
and NH out-of-plane bands were clearly seen, confirming the presence of this protein.
Measurements of  potential in aqueous colloidal suspensions showed representative changes on 
the superficial charge, with values of -21.5, -33.5, and -25.3 mV for MSN, MSNSATES, and 
MSNConA, respectively.
The functionalization degree of the particles was calculated as the difference between TGA 
measures, finding 18% of SATES in MSNSATES and 11% of protein in the final system MSNConA. 
As expected, the pore volume of the MSN suffers a decrease with increasing surface decoration. 
Thus, the specific surface area changes from 907 in the case of the naked material MSN to 240 
m2/g in the case of the complete system MSNConA.
Structural characterization by TEM (Fig. 4A-D) showed spherical nanoparticles with an average 
size of ca. 150 nm and a honeycomb mesoporous arrangement before and after functionalization 
and anchoring of the ConA. Moreover, all samples exhibited typical MCM-41 structure with a 2D 
hexagonal structure, which is also confirmed by XRD studies (Fig. S1). In this case, a small 
reduction in the intensity of the XRD peaks was observed for MSNSATES and MSNConA, which is 
due to the slight order loss ascribed to the partial filling of the mesopore channels by the 
functionalization agent. In addition, after staining with 1% PTA, both samples that contained 
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ConA (MSNConA and MSNConA@LEVO) showed that the protein covered all external surfaces of 
the nanoparticles, hence retaining the spherical morphology even after loading win LEVO as 
shown in Fig. 4D. To acquire information of the mean size and stability of the nanosystems in 
solution, DLS measurements were recorded (Fig. S2). The measurements performed in Milli-Q 
H2O showed a small increase in the hydrodynamic radius of the particles after functionalization 
with SATES and ConA. 
3.2. In vitro LEVO release 
The amount of LEVO loaded into nanoparticles was determined by elemental chemical analysis 
and TGA as 3.0 and 3.8% in weight for MSN@LEVO and MSNConA@LEVO, respectively, which 
is comparable with that mentioned in other studies based on silica mesoporous materials [12,28].  
The in vitro drug release assays from different samples were carried out in PBS at 37ºC under 
orbital stirring. Fig. 5 shows in vitro release profiles, which are expressed as accumulative drug 
release as function of time. The results indicate that both release curves can be adjusted to first-
order kinetics, with the release rate faster and significantly higher after ConA grafting. Moreover, 
MSN@LEVO partially retains the loaded drug, with the maximum drug released, ca. 30%, after 
48 h, which is in accordance with previous results [12,29]. On the contrary, MSNConA@LEVO 
released almost the total amount of loaded antibiotic after 5 days of assay. Previous studies have 
revealed that there is a strong interaction between the LEVO molecules and silica network in 
MSNs through hydrogen bonding between the zwitterionic form of this quinolone antibiotic at pH 
7.4 and Si-OH groups of silica nanoparticles.Error! Bookmark not defined. Thus, the bare MSN sample 
partially retains the loaded LEVO, releasing approximately 30% after 2 days of assay. On the 
contrary, the presence of the ConA protein on the external surface promotes the interaction with 
LEVO molecules, which provokes drug departure from the mesopores, hence resulting in a faster 
antibiotic release.
Additionally, the biological activity of each antibiotic dose at different tested times was also 
evaluated by incubation with E. coli suspensions (108 bacteria/mL) and subsequent counting of 
colony-forming units (CFUs). Antimicrobial efficacy after 2 days and 5 days for MSN@LEVO 
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and MSNConA@LEVO, respectively, was observed (Fig. S3), which was in good agreement with 
the results of kinetics studies.
In general, the drug release kinetics from mesoporous matrices are governed, primarily by drug 
diffusion processes throughout the matrix. Such drug diffusion processes are fitted, generally, to 
the Higuchi model. However, our results suggest that in addition to the drug diffusion process 
throughout the mesoporous matrix, a new component is governing the drug release kinetics. 
Specifically, this new component refers to the silica matrix–LEVO interactions, as it has been 
previously reported for other silica matrices. 
3.3. In vitro internalization assays (targeting effect)
After demonstrating the antimicrobial capacity of the nanoantibiotic, the next step consisted in 
evaluating its bacterial biofilm-targeting efficacy. For this purpose, a preformed E. coli biofilm 
was incubated with different concentrations (5, 10, and 50 µg/mL) of nanoparticle suspensions. To 
solely evaluate the targeting effect, LEVO-free nanosystems were used, and confocal microscopy 
studies were conducted at different depths. To visualize the nanoparticles, they were labeled in red 
with rhodamineB (RhB). Fig. 6 shows the internalization study of pristine MSN and MSNConA in a 
preformed E. coli biofilm after 90 min of incubation and 50 μg/mL of nanoparticles, chosen as a 
representative concentration. 3D confocal reconstruction showed a typical biofilm structure, live 
bacteria (green) covered by a protective polysaccharide matrix (blue), where MSNs are localized 
onto its surface (see white arrows). These results are consistent with those published in other 
studies. In 2014, Forier et al. investigated the effect of nanoparticle size in biofilm penetration, 
indicating that the cutoff size for optimal penetration was approximately 130 nm [30]. Specifically 
for MSN, D. L. Slomberg et al. synthesized nanoparticles of two sizes (14 and 150 nm) and 
studied their diffusion into Pseudomonas aeruginosa biofilm. They observed that diffusion was 
also size dependent, and although both MSNs penetrated into the biofilm, the process was higher 
and faster for the smaller ones [31]. Therefore, it was expected that our pristine MSN, whose size 
(150 nm) is within the limit described, would be mainly retained on the surface of the biofilm. On 
the contrary, it is surprising that MSNConA are able to penetrate the biofilm and be placed at 
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different depth levels along the z-axis, suggesting that the effect of ConA is so powerful that it 
forces the internalization of nanoparticles whose size is theoretically inadequate. It is also worth 
mentioning that the MSNConA internalization degree is dose dependent, that is, the greater the 
concentration of the added nanoparticles, the higher is the amount of nanoparticles penetrating the 
biofilm (Fig. S4). MSNConA, with a -potential of -25 mV, could have a strong electrostatic affinity 
toward the polysaccharide of the biofilm matrix [32]. Moreover, this targeting agent has shown a 
selective affinity to α-mannopyranosyl and α-glucopyranosyl residues present in the extracellular 
polysaccharide matrix, which could explain the internalization mechanism of the MSNConA system 
into bacterial biofilm [18]. 
 3.4. Antimicrobial effects against gram-negative E. coli biofilm
Once the nanosystem has reached the biofilm, the anti-bacterial activity is determined by the 
physicochemical properties of the antimicrobial agent entrapped inside the nanosystem. Among 
others, LEVO, a synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity 
of bacterial DNA gyrase, halting DNA replication, is a broad-spectrum antibiotic that provides 
clinical and bacteriological efficacy for a range of infections [33]. However, previous studies [12] 
have proved its inefficiency once the biofilm has been formed. To solve that, LEVO has been 
incorporated to the mesostructured arrangement of these targeted nanosystems to be released 
within the biofilm. For this purpose, a preformed E. coli biofilm was incubated with different 
concentrations (5, 10, and 50 µg/mL) of loaded nanoparticles (Fig. S5), with 10 µg/mL as the most 
optimum antibiofilm concentration.
Fig.7 shows the in vitro antimicrobial efficacy against preformed E. coli biofilms after 90 min of 
incubation with a suspension of 10 µg/mL of MSN, MSN@LEVO, MSNConA, and 
MSNConA@LEVO. The confocal microscopy image corresponding to control (Fig. 7C) shows a 
typical biofilm formed mainly by a mantle of live bacteria (green), with some dead bacteria (red) 
isolated and covered with a polysaccharide matrix represented in blue. The results show that 
samples treated with MSN present a small reduction in the biofilm (Fig. 7A). After treatment with 
MSN@LEVO (Fig. 7B), the reduction is more visible, with gaps appearing on its surface, 
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probably due to a more superficial action of the antibiotic because the particles practically did not 
penetrate into the biofilm but still showed a large amount of live bacteria. This reduction, in terms 
of percentage, corresponds to 50% of live bacteria and 70% for covered biofilm for bare 
MSN@LEVO, hence showing its antimicrobial inefficiency. On the contrary, this scenario totally 
changes after treatment with MSNConA (Fig. 7D), where a significant reduction of the biofilm is 
observed, even in the absence of the LEVO. Undoubtedly, this increase in antimicrobial capacity 
must be due to the presence of ConA. A study of the effect produced in the biofilm by the 
MSNConA sample shows a notable reduction in biofilm of 65% (green scatter) and 75% (blue 
scatter) (see Fig.7F). More experiments are necessary to elucidate the mechanism of ConA toxicity 
in the biofilm. However, we hypothesized that it could be similar to that observed for some other 
lectins [34-36]. Finally, Figure 7E shows that the biofilm treated with MSNConA@LEVO suffered a 
complete eradication, showing only a few scatter of bacteria (mostly dead/red). An in-depth 
analysis of the surface, calculated using ImageJ software, showed a reduction of almost 99.9% of 
live bacteria and almost 100% of blue-covered biofilm for the targeted nanosystems. These results 
evidence that the incorporation of ConA as a biofilm-targeting agent onto the MSN surface 
platform triggers complete biofilm destruction in combination with the antibiotic. In this sense, 
because of the penetration of these nanosystems into the biofilm and the release of the antibiotic 
inside it, a high antimicrobial efficacy is produced. On the contrary, treatment with bare 
MSN@LEVO provokes a reduction in the biofilm area, but the effect was significantly less 
effective owing to the lack of penetration into the biofilm. In addition, to determine the antibiofilm 
effect of MSN samples and confirm the effective dosage, the bacteria present in the biofilm 
after treatment were counted by the drop plate method. Fig. 8 shows the reduction in 
percentage of biofilm in terms of CFU per mL with regard to control after treatment. The 
obtained results show a notable reduction of 97.8% and 100% for 10 and 20 mg/mL for 
MSNConA@LEVO, respectively, which are in agreement with the results of confocal 
microscopy (Fig.7D). Note that the dose at 10 g/mL shows a bacterial concentration of 




The use of these nanocarriers for clinical applications in infection treatment requires that the 
designed material present excellent biocompatibility and absence of cytotoxicity. MSN is a 
biocompatible material that exhibits low toxicity and lack of immunogenicity and is degraded into 
nontoxic compounds (mainly silicic acid) in relatively short time periods [38]. Despite its lack of 
toxicity, the surface modification of this MSN could provoke toxicity because of enhanced uptake 
within the cells. To evaluate toxicity, MC3T3-E1 cells were incubated with different amounts of 
the MSNs in cell culture medium for 24 h. After incubation, cell viability was determined using 
the standard cell viability test by MTS reduction. The results showed that none of these empty 
materials exhibited cytotoxicity in either cell line (Fig. 9), which was in agreement with previous 
results [19]. 
4. Conclusions
In this work, a new class of targeting antimicrobial device based on mesoporous silica 
nanoparticles (MSNs) decorated with ConA and loaded with LEVO as the antibiotic has been 
developed. The covalent grafting of ConA to MSNs (MSNConA) allows an effective penetration in 
gram-negative bacteria biofilm, which increases the antimicrobial efficacy of LEVO hosted in the 
mesopores. These findings demonstrate that the synergistic combination of biofilm internalization 
and antimicrobial agents into a unique nanosystem provokes a remarkable antimicrobial effect 
against bacterial biofilm. This nanocarrier is a promising alternative to the current available 
treatments for the management of infection. The next step in future studies is to determine its 
clinical relevance by in vivo models in wounds or after implant and prosthesis application.
Appendix A. Supplementary data




This work was supported by European Research Council, ERC-2015-AdG (VERDI), Proposal No. 
694160. 
References 
[1] G. Taubes, The Bacteria Fight Back, Science. 321 (2008) 356–361. 
[2] M.E.A. de Kraker, A.J. Stewardson, S. Harbarth, Will 10 Million People Die a Year 
due to Antimicrobial Resistance by 2050?, PLOS Med. 13 (2016) e1002184.
[3] R.R. Bragg, C.M. Meyburgh, J.-Y. Lee, M. Coetzee, Potential Treatment Options in a 
Post-antibiotic Era, in: R. Adhikari, S.Thapa (Eds.), Infect. Dis. Nanomedicine III. Adv. 
Exp. Med. Biol., Springer, Singapore, 2018: pp. 51–61. 
[4] Z. Chen, H. Ji, C. Liu, W. Bing, Z. Wang, X. Qu, A Multinuclear Metal Complex 
Based DNase-Mimetic Artificial Enzyme: Matrix Cleavage for Combating Bacterial 
Biofilms, Angew. Chemie Int. Ed. 55 (2016) 10732–10736. 
[5] Y. Zhang, P. Sun, L. Zhang, Z. Wang, F. Wang, K. Dong, Z. Liu, J. Ren, X. Qu, 
Silver-Infused Porphyrinic Metal-Organic Framework: Surface-Adaptive, On-Demand 
Nanoplatform for Synergistic Bacteria Killing and Wound Disinfection, Adv. Funct. 
Mater. 29 (2019) 1808594. 
[6] D. Campoccia, L. Montanaro, C.R. Arciola, The significance of infection related to 
orthopedic devices and issues of antibiotic resistance, Biomaterials. 27 (2006) 2331–2339. 
[7] D. Lebeaux, J.-M. Ghigo, C. Beloin, Biofilm-Related Infections: Bridging the Gap 
between Clinical Management and Fundamental Aspects of Recalcitrance toward 
Antibiotics, Microbiol. Mol. Biol. Rev. 78 (2014) 510–543. 
[8] M. Vallet-Regi, A. Rámila, R.P. del Real, J. Pérez-Pariente, A New Property of MCM-
41:  Drug Delivery System, Chem. Mater. 13 (2001) 308–311. 
[9] M. Vallet-Regí, M. Colilla, I. Izquierdo-Barba, M. Manzano, Mesoporous Silica 
Nanoparticles for Drug Delivery: Current Insights, Molecules. 23 (2017) 47. 
[10] R.R. Castillo, D. Lozano, B. Gonzalez, M. Manzano, I. Izquierdo-Barba, M. Vallet-
Regi, Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug 
delivery: an update. Expert Opin. Drug Deliv. 16 (2019) 415–439. 
[11] M. Martínez-Carmona, Y. Gun’ko, M. Vallet-Regí, Mesoporous Silica Materials as 
Drug Delivery: “The Nightmare” of Bacterial Infection, Pharmaceutics. 10 (2018) 279. 
[12] B. González, M. Colilla, J. Díez, D. Pedraza, M. Guembe, I. Izquierdo-Barba, M. 
Vallet-Regí, Mesoporous Silica Nanoparticles Decorated with Polycationic Dendrimers 
for Infection Treatment, Acta Biomater. 68 (2018) 261–271
  
18
[13] D. Pedraza, J. Díez, Isabel-Izquierdo-Barba, M. Colilla, M. Vallet-Regí, Amine-
Functionalized Mesoporous Silica Nanoparticles: A New Nanoantibiotic for Bone 
Infection Treatment, Biomed. Glas. 4 (2018) 1–12.
[14] P. V. Baptista, M.P. McCusker, A. Carvalho, D.A. Ferreira, N.M. Mohan, M. 
Martins, A.R. Fernandes, Nano-Strategies to Fight Multidrug Resistant Bacteria—“A 
Battle of the Titans,” Front. Microbiol. 9 (2018). 
[15] T.H.R. Niepa, L. Vaccari, R.L. Leheny, M. Goulian, D. Lee, K.J. Stebe, Films of 
Bacteria at Interfaces (FBI): Remodeling of Fluid Interfaces by Pseudomonas aeruginosa, 
Sci. Rep. 7 (2017) 17864. 
[16] H. Rüdiger, Isolation of Plant Lectins, in: H. Gabius, S. Gabius (Eds.), Lectins 
Glycobiol., Springer Berlin Heidelberg, Berlin, Heidelberg, 1993: pp. 31–46. 
[17] R.D. Cummings, A.G. Darvill, M.E. Etzler, M.G. Hahn, Glycan-Recognizing Probes 
as Tools, 2015. doi:10.1101/glycobiology.3e.048.
[18] D.H. Dube, C.R. Bertozzi, Glycans in cancer and inflammation — potential for 
therapeutics and diagnostics, Nat. Rev. Drug Discov. 4 (2005) 477–488.
[19] M. Martínez-Carmona, D. Lozano, M. Colilla, M. Vallet-Regí, Lectin-conjugated 
pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment, Acta 
Biomater. 65 (2017) 393–404.
[20] E.N. Tang, A. Nair, D.W. Baker, W. Hu, J. Zhou, In Vivo Imaging of Infection Using 
a Bacteria-Targeting Optical Nanoprobe, J. Biomed. Nanotechnol. 10 (2014) 856–863. 
[21] J.J.B. Jandú, R.N. Moraes Neto, A. Zagmignan, E.M. de Sousa, M.C.A. Brelaz-de-
Castro, M.T. dos Santos Correia, L.C.N. da Silva, Targeting the Immune System with 
Plant Lectins to Combat Microbial Infections, Front. Pharmacol. 8 (2017) 1–11.
[22] T. Paunova-krasteva, S.R. Stoitsova, T. Topouzova, Escherichia coli O157 : 
Effects of growth temperature on concanavalin a binding and the adherence to cultured 
cells, Comptes Rendus l’Acad´emie Bulg. Des Sci. 64 (2014).
[23] M. Strathmann, J. Wingender, H. Flemming, Application of fluorescently labelled 
lectins for the visualization and biochemical characterization of polysaccharides in 
biofilms of Pseudomonas aeruginosa, J. Microbiol. Methods. 50 (2002) 237–248.
[24] M. Amine Ben Mlouka, T. Cousseau, P. Di Martino, Application of fluorescently 
labelled lectins for the study of polysaccharides in biofilms with a focus on biofouling of 
nanofiltration membranes, AIMS Mol. Sci. 3 (2016) 338–356. 
[25] S.P. Vyas, V. Sihorkar, P.K. Dubey, Preparation, characterization and in vitro 
antimicrobial activity of metronidazole bearing lectinized liposomes for intra-periodontal 
  
19
pocket delivery., Pharmazie. 56 (2001) 554–60. 
[26] B. Herigstad, M. Hamilton, J. Heersink. How to optimize the drop plate method for
enumerating bacteria. Journal of microbiological methods. 44 (2001)121–129.
[27] M. Grün, I. Lauer, K.K. Unger, The synthesis of micrometer- and submicrometer-size 
spheres of ordered mesoporous oxide MCM-41, Adv. Mater. 9 (1997) 254–257.
[28] M. Cicuéndez, J.C. Doadrio, A. Hernández, M.T. Portolés, I. Izquierdo-Barba, M. 
Vallet-Regí, Multifunctional pH sensitive 3D scaffolds for treatment and prevention of 
bone infection. Acta Biomaterialia 65 (2018) 450–461.
[29] Y. Wang, W. Baeyens, C. Huang, G. Fei, L. He, J. Ouyang, Enhanced separation of 
seven quinolones by capillary electrophoresis with silica nanoparticles as additive, 
Talanta. 77 (2009) 1667–1674.
[30] K. Forier, A.-S. Messiaen, K. Raemdonck, H. Nelis, S. De Smedt, J. Demeester, T. 
Coenye, K. Braeckmans, Probing the size limit for nanomedicine penetration into 
Burkholderia multivorans and Pseudomonas aeruginosa biofilms, J. Control. Release. 195 
(2014) 21–28.
[31] D.L. Slomberg, Y. Lu, A.D. Broadnax, R.A. Hunter, A.W. Carpenter, M.H. 
Schoenfisch, Role of Size and Shape on Biofilm Eradication for Nitric Oxide-Releasing 
Silica Nanoparticles, ACS Appl. Mater. Interfaces. 5 (2013) 9322–9329.
[32] Z. Rukavina, Ž. Vanić, Current trends in development of liposomes for targeting 
bacterial biofilms, Pharmaceutics. 8 (2016).
[33] G.J. Noel, A Review of Levofloxacin for the Treatment of Bacterial Infections, 
Clin. Med. Ther. 1 (2009) CMT.S28. 
[34] R.C. Klein, M.H. Fabres-Klein, L. Licursi De Oliveira, R.N. Feio, F. Malouin, A. 
De Oliveira Barros Ribon, A C-type lectin from Bothrops jararacussu venom disrupts 
staphylococcal biofilms, PLoS One. 10 (2015) 1–16. 
[35] A.A. Alyousef, A. Alqasim, M.S. Aloahd, Isolation and characterization of lectin 
with antibacterial, antibiofilm and antiproliferative activities from Acinetobacter 
baumannii of environmental origin, J. Appl. Microbiol. 124 (2018) 1139–1146. 
[36] M.A. Vasconcelos, F.V.S. Arruda, V.A. Carneiro, H.C. Silva, K.S. Nascimento, 
A.H. Sampaio, B. Cavada, E.H. Teixeira, M. Henriques, M.O. Pereira, Effect of Algae and 
Plant Lectins on Planktonic Growth and Biofilm Formation in Clinically Relevant 
Bacteria and Yeasts, Biomed Res. Int. 2014 (2014) 1–9. 
[37] S.A.J. Zaat, C.A.N. Broekhuizen, M. Riool, Host tissue as a niche for biomaterial 
associated infection, Fut. Microbiol. 5 (2010) 1149–1151.
  
20
[38] J. Lu, M. Liong, Z. Li, J.I. Zink, F. Tamanoi, Biocompatibility, Biodistribution, and 
Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in 
Animals. Small 6 (2010) 1794−1805.
Figure captions
Fig. 1. Schematic illustration of the aim of thisstudy. 
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Fig. 2. Schematic depiction of the synthesis procedure used to develop our nanoantibiotic: 
(i) Functionalization with carboxylic groups (MSNSATES); (ii) surfactant extraction; (iii) 




Fig. 3. FTIR spectra of MSN, MSNSATES, and MSNConA, confirming the effectiveness of 
the functionalization process.  
Fig. 4. TEM images of (A) pristine MSN, (B) MSNSATES, (C) MSNConA, and (D) 
MSNConA@LEVO, respectively. After functionalization with the organic compound, the 






























Fig. 5. In vitro LEVO release profiles (n = 3) from MSNConA and MSN in PBS at 37ºC and 
orbital stirring. The amount of LEVO released was determined by fluorescence 
measurements of the solutions, (λex = 292 nm, λem = 494 nm) and expressed as 
accumulative drug release as function of time. 
  
24
Fig. 6. Confocal microscopy study of the internalization of red-labeled pristine MSN and 
MSNConA in preformed E. coli biofilms after 90 min of incubation with 50 μg/mL of 
nanoparticles. 3D confocal reconstruction shows that bare MSNs are localized onto the 
biofilm surface, whereas MSNConA penetrate the biofilm and are placed at different depth 
levels. Live bacteria are stained in green (SYTO), nanoparticles in red (RhB), and the 
extracellular polysaccharide biofilm matrix in blue (Calcofluor). Scale bars, 20 µm.
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Fig. 7. Confocal microscopy study of the antimicrobial activity of the LEVO-loaded MSN 
materials on the gram-negative E. coli biofilm. The images show (A) the biofilm 
preformed onto a covered glass disk without treatment (control) and after 90 min of 
incubation with (B) MSN@LEVO and (C) MSNConA@LEVO, respectively. Live bacteria 
are stained in green, dead bacteria in red, and the protective matrix biofilm in blue. Scale 
bars, 20 µm. (D) Histogram representing the percentage covered surface in green and blue 
from eight confocal images and calculated by ImageJ software (National Institutes of 
Health, Bethesda, MD) after treatment with 10 g/mL of different nanoparticles. The 
numerical data represent the percentage of reduction in each case with regard to control (in 
the absence of any nanoparticle treatment). Experiments were performed in triplicate. *p 
<0.05 vs. corresponding MSN@LEVO and MSNConA (ANOVA). 
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Fig. 8 Effect of the samples on E. coli biofilm at different concentrations of the samples 
after 24 h. Results are represented as the reduction percentage with regard to control in the 
absence of nanoparticles. *p <0.05 vs. corresponding MSN@LEVO (ANOVA). 
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Fig. 9. Cell viability studies of the samples at different concentrations for the MC3T3-E1 
cell line with 24 h of exposure time. *p <0.05 vs. corresponding control without 
nanoparticles (ANOVA). 
